Advertisement
Gioacchino De Chirico, President & CEO of Immucor, said, "We are pleasedto have completed this acquisition, which we believe will enable us to provideinnovative molecular diagnostic solutions for blood transfusions to enhancepatient outcomes."
Advertisement
Immucor expects to provide more information about the BioArray acquisitionon its investors conference call in October to review the results of its firstfiscal quarter.
Founded in 1982, Immucor manufactures and sells a complete line ofreagents and systems used by hospitals, reference laboratories and donorcenters to detect and identify certain properties of the cell and serumcomponents of blood prior to transfusion. Immucor markets a complete family ofautomated instrumentation for all of our market segments.
For more information on Immucor, please visit our website athttp://www.immucor.com .
Statements contained in this press release that are not statements ofhistorical fact are "forward-looking statements" as that term is defined underfederal securities laws, including, without limitation, all statementsconcerning Immucor's expectations, beliefs, intentions or strategies for thefuture. Factors related to the BioArray acquisition that could adverselyaffect the Company's results include but are not limited to: the ability ofthe Company to successfully develop an automated platform for BioArray'stransfusion genotyping system, and the cost to do so; the ability of theCompany to gain FDA clearance for that automated platform; the acceptance ofBioArray technology in transfusion and transplantation markets; and the costto successfully market and sell products incorporating BioArray technology.Further risks concerning the Company's business are detailed in the Company'sfilings with the Securities and Exchange Commission. Investors are cautionednot to place undue reliance on any forward-looking statements. Immucorassumes no obligation to update any forward-looking statements.
SOURCE Immucor, Inc.
